Analysts Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Price Target at $10.08

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $10.0833.

Several equities analysts have issued reports on the company. Zacks Research lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 30th. Barclays started coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They issued an “overweight” rating and a $9.00 price objective for the company. Piper Sandler increased their target price on shares of Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Oppenheimer restated an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th.

Insider Buying and Selling at Xeris Biopharma

In other news, Director John Johnson sold 135,400 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $7.22, for a total transaction of $977,588.00. Following the transaction, the director directly owned 698,083 shares of the company’s stock, valued at $5,040,159.26. This represents a 16.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Beth Hecht sold 16,667 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $7.01, for a total value of $116,835.67. Following the completion of the transaction, the insider owned 1,320,176 shares in the company, valued at approximately $9,254,433.76. This represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 263,550 shares of company stock worth $1,918,506 in the last quarter. Company insiders own 4.56% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of XERS. AlphaQuest LLC bought a new stake in shares of Xeris Biopharma during the third quarter worth about $35,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after acquiring an additional 1,820 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in Xeris Biopharma during the 3rd quarter valued at about $68,000. Finally, Kingsview Wealth Management LLC bought a new stake in Xeris Biopharma during the 4th quarter worth approximately $78,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Up 3.7%

XERS stock opened at $7.22 on Friday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -72.19 and a beta of 0.52. The company’s fifty day simple moving average is $7.29 and its 200 day simple moving average is $7.57. Xeris Biopharma has a 12-month low of $3.44 and a 12-month high of $10.08.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.